Background Apremilast, an oral phosphodiesterase‐4 inhibitor, has demonstrated efficacy in
patients with moderate to severe psoriasis. Objective To evaluate long‐term efficacy and …

Background Apremilast, an oral, small‐molecule phosphodiesterase 4 inhibitor, has
demonstrated efficacy in patients with moderate‐to‐severe psoriasis. Objective Evaluate …

Background APPRECIATE is a multinational, observational, retrospective, cross‐sectional
study in patients treated for psoriasis with apremilast, an oral phosphodiesterase 4 inhibitor …

Background Psoriasis is a chronic inflammatory skin disease, which requires long‐term, safe
and effective treatment. Apremilast, a small‐molecule PDE 4 inhibitor, has been introduced …

Background Apremilast is a novel oral phosphodiesterase‐4 inhibitor approved for psoriasis
treatment. Randomized trials have documented its efficacy and safety, but data on real …

Abstract Introduction/Background Manifestations of psoriasis in special areas are difficult to
treat and are associated with a high disease burden and significant quality of life (QoL) …

Background Apremilast, an oral phosphodiesterase 4 inhibitor, regulates immune responses
associated with psoriasis. Objectives ESTEEM 2 evaluated the efficacy and safety of …

Apremilast is a novel oral phosphodiesterase 4 inhibitor effective for psoriasis. It regulates
the production of pro‐inflammatory mediators. Apremilast was approved in December 2016 …

Background Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works
intracellularly to modulate pro‐inflammatory and anti‐inflammatory mediator production …

Background Little has been published on the real‐world effectiveness and safety of
apremilast in psoriasis. Objectives To evaluate the effectiveness, safety and drug survival of …